Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

NKTR – Nektar Therapeutics

NKTR — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

12.59

Margin Of Safety %

Put/Call OI Ratio

0.79

EPS Next Q Diff

1.27

EPS Last/This Y

0.19

EPS This/Next Y

-3.02

Price

66.62

Target Price

153.25

Analyst Recom

1.2

Performance Q

-9.52

Upside

-264.3%

Beta

-0.82

Ticker: NKTR




22 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-04-23NKTR91.20.541.1342037
2026-04-24NKTR91.580.572.4842999
2026-04-27NKTR86.740.590.6343690
2026-04-28NKTR84.610.600.5444571
2026-04-29NKTR83.140.594.0945951
2026-04-30NKTR85.030.620.1046953
2026-05-01NKTR86.450.620.3647281
2026-05-04NKTR86.830.620.7447334
2026-05-05NKTR84.150.610.5248238
2026-05-06NKTR84.960.600.1448471
2026-05-07NKTR83.40.600.2748511
2026-05-08NKTR81.740.610.3448257
2026-05-11NKTR78.830.600.4448398
2026-05-12NKTR78.420.612.5548475
2026-05-13NKTR75.950.671.2551059
2026-05-14NKTR74.670.651.3550214
2026-05-15NKTR70.670.630.4649913
2026-05-18NKTR68.530.840.5728932
2026-05-19NKTR67.590.840.4929776
2026-05-20NKTR69.490.840.6030151
2026-05-21NKTR68.550.830.0330473
2026-05-22NKTR66.590.790.2330312
DateSymbolLatestP/C OIP/C VolTotal OI
22 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-04-23NKTR91.1955.6- -9.11
2026-04-24NKTR91.6655.6- -9.11
2026-04-27NKTR86.7855.6- -9.05
2026-04-28NKTR83.7959.0- -8.54
2026-04-30NKTR85.0459.0- -8.54
2026-05-01NKTR86.5359.0- -8.54
2026-05-04NKTR86.8659.0- -8.54
2026-05-05NKTR84.1959.0- -8.54
2026-05-06NKTR84.9659.0- -8.54
2026-05-07NKTR83.3759.0- -8.54
2026-05-08NKTR81.7459.0- -8.54
2026-05-11NKTR78.7440.7- -8.71
2026-05-12NKTR78.4725.1- -9.44
2026-05-13NKTR75.9726.7- -9.44
2026-05-14NKTR74.3426.7- -9.54
2026-05-15NKTR70.7926.7- -9.54
2026-05-18NKTR68.4826.7- -9.54
2026-05-19NKTR67.5726.7- -9.54
2026-05-20NKTR69.4926.7- -9.54
2026-05-21NKTR68.5626.7- -9.54
2026-05-22NKTR66.6226.7- -9.54
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




22 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-04-23NKTR-1.3124.220
2026-04-24NKTR-1.3124.2212.62
2026-04-27NKTR-1.3118.0812.50
2026-04-28NKTR-1.3118.0812.50
2026-04-29NKTR-1.1718.0811.17
2026-04-30NKTR-1.1718.0811.17
2026-05-01NKTR-1.1718.0811.17
2026-05-04NKTR-1.1718.7011.17
2026-05-05NKTR-1.1718.7011.17
2026-05-06NKTR-1.1718.7011.17
2026-05-07NKTR-1.1718.7011.17
2026-05-08NKTR-1.1718.7011.17
2026-05-11NKTR-1.1724.5511.17
2026-05-12NKTR-1.1724.5512.62
2026-05-13NKTR-1.1524.5512.41
2026-05-14NKTR-1.1524.5512.41
2026-05-15NKTR-1.1524.5512.41
2026-05-18NKTR-1.1523.1512.37
2026-05-19NKTR-1.3323.1512.37
2026-05-20NKTR-1.3323.1512.37
2026-05-21NKTR-1.3323.1512.59
2026-05-22NKTR-0.7623.1512.59
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
22 items Current Page1 of 1

Last Quarter Act. EPS

-1.78

Avg. EPS Est. Current Quarter

-2.04

Avg. EPS Est. Next Quarter

-0.52

Insider Transactions

-0.76

Institutional Transactions

23.15

Beta

-0.82

Average Sales Estimate Current Quarter

10

Average Sales Estimate Next Quarter

10

Fair Value

Quality Score

32

Growth Score

23

Sentiment Score

51

Actual DrawDown %

77.1

Max Drawdown 5-Year %

-97.8

Target Price

153.25

P/E

Forward P/E

PEG

P/S

40.45

P/B

2.36

P/Free Cash Flow

EPS

-8.42

Average EPS Est. Cur. Y​

-9.54

EPS Next Y. (Est.)

-12.56

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-284.18

Relative Volume

0.52

Return on Equity vs Sector %

-54.5

Return on Equity vs Industry %

-38.9

EPS 1 7Days Diff

-1

EPS 1 30Days Diff

0.47

EBIT Estimation

NKTR Healthcare
$66.61
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
14/20
Pullback
15/25
Volume
11/15
Valuation
10/20
TP/AR
4/10
Options
5/10
RSI
31
Range 1M
6.3%
🚀
Momentum Growth
Ride accelerating trends
N/A
33 /100
WEAK
Momentum
7/25
Growth
12/30
Estimates
2/20
Inst/Vol
6/15
Options
6/10
EPS Yr
6.9%
EPS NY
-22.2%
52W%
58.2%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +130.1% upside
Quality
6/30
Valuation
16/30
Growth
6/25
Stability
7/10
LT Trend
0/5
Upside
+130.1%
Quality
32
Nektar Therapeutics
Sector: Healthcare
Industry: Biotechnology
Employees: 63
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.
NKTR

Latest News

Caricamento notizie per NKTR
stock quote shares NKTR – Nektar Therapeutics Stock Price stock today
news today NKTR – Nektar Therapeutics stock forecast ,stock prediction 2023 2024 2025
marketwatch NKTR – Nektar Therapeutics yahoo finance google finance
stock history NKTR – Nektar Therapeutics invest stock market
stock prices NKTR premarket after hours
ticker NKTR fair value insiders trading